Briakinumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. Briakinumab binds to both IL-12 and IL-23, which prevents IL-12- and IL-23-mediated signaling. This may suppress immune responses mediated by these interleukins. The cytokines IL-12 and IL-23 play an important role during inflammation.

**Synonyms:** - A-796874.0 - ABT-874 - BRIAKINUMAB - BSF-415977 - Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit Beta (IL-12 Subunit P40, CLMF P40 or NKSF2)); Human Monoclonal Gamma-1 Heavy Chain (218-216')-Disulfide with Human Monoclonal Gamma Light Chain, Dimer (224-224'':227-227'')-Bisdisulfide - J-695 - Kriakinumab - LU-415977 - Ozespa - WAY-165772